Sign in
Taking people in NetherlandsPhase 1/2

Tests tremelimumab injected through the airway in early lung cancer

Tests a drug injected by needle through the airway into early-stage lung cancer in adults.

Key facts

Who runs it
Amsterdam UMC Stichting
Where
Amsterdam, NetherlandsSee the site
Registry title
TransBronchial Needle injection of Tremelimumab in early-stage NSCLC patients (TALENT)
Status
Recruiting
Phase
Phase 1/2
People taking part
24 people, planned
Started
3 Nov 2025
Planned end
30 Apr 2026
Type of study
Interventional
Record updated
21 October 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with early-stage non-small cell lung cancer who are going to have the tumor removed by surgery. It tests a needle injection of tremelimumab given through a bronchoscope.

Age
Above 18 years
Sex
Men and women can join.
Disease stage
Non-small cell lung cancer confirmed by tissue testing, stage T1-2N0M0, scheduled for surgery to remove the lung tumor.
Earlier treatment
Cannot have had an anti-PD-1, anti-PD-L1 (including durvalumab), anti-PD-L2, anti-CTLA-4 antibody, or similar immune checkpoint drug in the past year.
Biomarker or test result
Cannot have known activating EGFR or BRAF mutations, or ALK or ROS1 gene rearrangements.

Main reasons for not taking part

  • Patients judged unable to have surgery
  • Pregnant or breastfeeding, or planning to conceive during the trial
  • Active or past autoimmune or inflammatory disease, with some listed exceptions
  • Active infection needing systemic treatment, or a history of HIV
  • Another cancer that is progressing or needs active systemic treatment

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Pathologically confirmed, T1-2N0M0 NSCLC scheduled for surgical lung tumor resection
  • Willing and able to provide written informed consent for the trial
  • Above 18 years of age on day of signing informed consent
  • Considered a surgical lung tumor resection candidate, as determined by the pulmonologist and lung surgeons at the multidisciplinary tumor meeting

Who cannot take part

  • Has received prior therapy with an anti-PD-1, anti-PD-L1 including durvalumab, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways in the past year
  • Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of day 0. Inhaled or topical steroids, and adrenal replacement steroid >10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
  • Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.]). The following are exceptions to this criterion: a. Patients with vitiligo or alopecia b. Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement c. Any chronic skin condition that does not require systemic therapy d. Patients without active disease in the last 5 years may be included but only after consultation with the study physician e. Patients with celiac disease controlled by diet alone
  • Additional malignancy that is progressing or requires active systemic treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy
  • Uncontrolled intercurrent illness, including but not limited to symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
  • Active infection requiring systemic therapy
  • A history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)
  • Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA
  • Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
  • Patients with known oncogenic drivers such as activating EGFR or BRAF mutations or ALK or ROS1 gene rearrangements
  • Patients deemed inoperable
  • Patient is pregnant or breastfeeding, or expecting to conceive within the projected duration of the trial, starting with the pre-screening or screening visit through 23 weeks after the bronchoscopy

Where in Netherlands

  • Stichting Amsterdam UMCAmsterdam, NetherlandsTaking people

About the trial

What the trial wants to find out

To study the safety and feasibility of intra-nodal and intra-tumoral bronchoscopic transbronchial needle injection (TBNI) of tremelimumab in early-stage NSCLC patients.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
TransBronchial Needle injection of Tremelimumab in early-stage NSCLC patients (TALENT)
Plain-language title
Tests tremelimumab injected through the airway in early lung cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
21 October 2024